TMOThermo Fisher
Pharma & Healthcare · US · Thermo Fisher Scientific Inc.
3 of 6 ratios computed · receipts verified server-side
The full receipt
Latest published value for each ratio, with the sector median for context and year-over-year change where the prior year is available.
- Markup →
How much revenue per dollar of cost.
Not computed: missing input.Needed but not in this company's XBRL filings: Cost of Goods Sold.What this company did disclose: Stock Buybacks, CEO Total Compensation, Dividends Paid, Median Employee Compensation, Net Income, Operating Expenses, R&D Expense, Revenue - Operational Markup →
Revenue per dollar of cost + operating expenses. The multiplier after legitimate operations.
Not computed: missing input.Needed but not in this company's XBRL filings: Cost of Goods Sold.What this company did disclose: Stock Buybacks, CEO Total Compensation, Dividends Paid, Median Employee Compensation, Net Income, Operating Expenses, R&D Expense, Revenue - Labor Share →
How much of every revenue dollar reaches workers.
Not computed: missing input.Needed but not in this company's XBRL filings: Total Employee Compensation.What this company did disclose: Stock Buybacks, CEO Total Compensation, Dividends Paid, Median Employee Compensation, Net Income, Operating Expenses, R&D Expense, Revenue - Executive Extraction →
How many times a CEO out-earns the median employee.
260.8× CEO / median workerverifiedCEO earns 261× the median workerSector median: 263.0Median range for extraction in sectorFY 2023v1.0.0 - Shareholder Extraction →
Dollars sent to shareholders for every dollar invested in R&D.
1.7034× buybacks+dividends / R&Dverified$1.70 to shareholders for every $1 in R&DSector median: 0.7492Top 24% for extraction in sectorFY 2023v1.0.0 - Capital Extraction →
How much of net profit goes to shareholders rather than back into the business.
0.3099× buybacks+dividends / net incomeverified31% of net profit returned to shareholders, 69% reinvestedSector median: 0.5294Median range for extraction in sectorFY 2023v1.0.0
Company response
No verified response yet. If you represent Thermo Fisher, you can add context, agree, or dispute.
Source data
Every raw line item this company disclosed in its XBRL filings. Click any filing to view the original on SEC.gov.
| Concept | Value | Unit | Period | Filing | Receipt |
|---|---|---|---|---|---|
CEO Total Compensation CEOTotalCompensation | 18,976,669 | USD | FY | 0001193125-24-090173 | verified |
Dividends Paid PaymentsOfDividendsCommonStock | 395,000,000 | USD | FY | 0000097745-24-000007 | verified |
Median Employee Compensation MedianEmployeeCompensation | 72,762 | USD | FY | 0001193125-24-090173 | verified |
Net Income ProfitLoss | 7,728,000,000 | USD | FY | 0000097745-24-000007 | verified |
Operating Expenses OperatingExpensesDerived(sum:SellingGeneralAndAdministrativeExpense+ResearchAndDevelopmentExpense) | 9,413,000,000 | USD | FY | 0000097745-24-000007 | verified |
R&D Expense ResearchAndDevelopmentExpense | 1,406,000,000 | USD | FY | 0000097745-24-000007 | verified |
Revenue RevenueFromContractWithCustomerExcludingAssessedTax | 39,211,000,000 | USD | FY | 0000097745-24-000007 | verified |
Stock Buybacks PaymentsForRepurchaseOfCommonStock | 2,000,000,000 | USD | FY | 0000097745-24-000007 | verified |